We have developed and patented extracts from Sideritis ssp. (Greek Mountain Tea), which have been shown in vitro
to be triple monamine reuptake inhibitors. This pharmacological profile
of Sideritis extracts suggests their use in the phytochemical therapy
of mental disorders associated with a malfunctioning monoaminergic
neurotransmission, like depressive disorders, panic attacs,
generalised anxiety disorders or the attention-deficit
hyperactivity disorder (ADHD). Sideritis extracts may be superior
to other plant extract in the therapy of these disorders, since the
long-term traditional use in the mediterranean area until now did not reveal side effects of the drug.
Several animal studies and observational studies with humans confirm this in vitro mechanism
of action. You may find some studies relevant for the understanding of
the CNS action of Sidertis extracts at the cross references on the left
We are convinced of the
pharmaceutical potential of Sideritis extract as CNS drugs and search
for interested cooperation partners to promote the development of
innovative herbal medicines.